Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Major depressive disorder ( MDD ) is a chronic mental illness that affects an estimated 5–26% of adults at some time in their lives. Treatment is often started as pharmacotherapy using a single drug such as a selective serotonin reuptake inhibitor. If a patient fails to respond adequately to the initial antidepressant, typically three pharmacotherapy options are available to the practitioner. The dose of the current therapy can be maximized, a change can be made to a different drug, or the current regimen can be augmented with another drug. Atypical antipsychotics have recently become a major focus for augmentation of traditional antidepressant therapy. This review summarizes the evidence for efficacy and safety of augmenting treatment‐refractory or treatment‐resistant depression with atypical antipsychotics. The National Library of Medicine's MEDLINE database was searched for all English‐language articles published from January 1966–December 2011 describing the use of atypical antipsychotics in treatment‐resistant depression. The literature retrieved was limited to case series, open‐label trials, and randomized controlled trials ( RCT ). Studies of bipolar depression, psychotic depression, or studies conducted in children and adolescents were excluded. Thirty‐five studies using atypical antipsychotics for augmentation treatment of depression were included in this analysis. Trials were identified for aripiprazole (six open‐label; three RCT ), clozapine (one case series), olanzapine (three open‐label, including two case series; four RCT ), quetiapine (four open‐label; five RCT ), risperidone (two open‐label; five RCT ), and ziprasidone (two open‐label). The atypical antipsychotics may be effective as adjunctive therapy in MDD ; however, their adverse effect profile may be unfavorable to some patients. Trying at least one alternative treatment strategy after an initial antidepressant is indicated before augmentation is implemented with these agents. If atypical antipsychotics are used, safety and efficacy should be frequently reassessed and dosage should be individualized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 2×
“As seen with buspirone augmentation in the STAR*D trial, 5-HT1A partial agonism can be a successful pharmacologic strategy for treatment-resistant depression.(5) In addition, quetiapine has an active metabolite, norquetiapine, which not only has partial agonist actions at 5-HT1A receptors, but also prevents NE reuptak…”
BackgroundMarcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260 · cited 2×
“5% of patients gaining more than 7% of their body weight, not significantly different from placebo.(18) A 52-week open-label extension was part of the two previously discussed trials 18 to assess short-term antidepressant response with aripiprazole add-on treatment for 14 weeks.”
BackgroundThase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Bauer, M., Pretorius, H. W., Constant, E. L., Earley, W. R., Szamosi, J., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04629 · Cited by 210
Corya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162 · cited 1×
“The combination of olanzapine and fluoxetine did not show a significant difference at study end point from other therapies including nortriptyline, but it did show a more rapid response.(24) A study was performed consisting of a 2–7 day screening phase, a 7-week prospective phase where all patients received venlafaxin…”
ResultMcIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140 · cited 2×
“Although no conclusion can be drawn relating to the efficacy of risperidone in combination with a specific antidepressant, the variety of agents used in this study may reflect actual clinical practice.(40) A double-blind, placebo-controlled, pilot study was conducted to investigate the efficacy of risperidone augmenta…”
BackgroundKeitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108 · cited 2×
“Lastly, a randomized, placebo-controlled trial that assessed the efficacy of risperidone augmentation in partial-responders or patients with no response to a 5-week open-label trial of an antidepressant was evaluated.(42) A total of 97 patients were randomized to receive risperidone or placebo (2:1) for 4 weeks and ri…”
BackgroundMethodReeves, H., Batra, S., May, R. S., Zhang, R., Dahl, D. C., & Li, X. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0805 · Cited by 102
Cited by
Reinforcement learning in depression: a review of computational research
Chen, C., Takahashi, T., Nakagawa, S., Inoue, T., & Kusumi, I. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.005 · Cited by 233
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182
Gaspersz, R., Nawijn, L., Lamers, F., & Penninx, B. W. J. H. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000376 · Cited by 139
Durgam, S., Earley, W., Guo, H., Li, D., Németh, G., Laszlovszky, I., Fava, M., & Montgomery, S. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10070 · Cited by 125
Faridhosseini, F., Sadeghi, R., Farid, L., & Pourgholami, M. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2401 · Cited by 89
Metadata
- Authors
- Wright, B. M., Eiland, E. H., & Lorenz, R.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2013-03
- Volume
- 33
- Issue
- 3
- Pages
- 344-359
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1998648170
- Cited by
- 84
- References
- 16
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.